Tevogen Inc. (TVGNW) company profile
Close on Oct 30, 2026Market cap $38.42MP/E –Yield –
About Tevogen
Biological Products, (No Diagnostic Substances), SIC 2836
Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company focused on developing off-the-shelf, precision T cell therapies for infectious diseases, cancers, and neurological disorders. Utilizing its proprietary ExacTcell technology, the company harnesses naturally occurring CD8+ cytotoxic T lymphocytes (killer T cells) to target multiple specific antigens without genetic engineering. Its leading clinical product candidate, TVGN 489, is being developed for the treatment and prevention of COVID-19 and Long COVID, particularly in high-risk elderly and immunocompromised patients. The company’s pipeline also includes investigational therapies targeting viral infections and oncology indications.
The company operates in the biotechnology and healthcare sector, seeking to serve large or underserved patient populations affected by life-threatening illnesses. Its clinical operations and principal executive offices are located in Warren, New Jersey.
Summary of the business section of Tevogen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Tevogen Inc.
- Headquarters
- Warren, NJ
- Address
- 15 Independence Boulevard, Suite #210 07059
- Phone
- (646) 807-8832
- Website
- tevogen.com
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- TVGNW
- Other tickers
- TVGN
- Exchange
- Nasdaq
- IPO date
- Nov 5, 2021
- Shares outstanding
- 7M, Aug 10, 2026
- Public float
- $63.70M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-50 reverse, Mar 6, 2026
- SEC CIK
- 1860871
- CUSIP
- 88165K119
- ISIN
- US88165K1198
- FIGI
- BBG013DG6CQ1
- LEI
- 549300AC21G4NBK9D322
- EIN
- 98-1597194
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ryan H. Saadi | Chief Executive Officer, Director | 11,709,567 |
| Kirti Desai | Chief Financial Officer | 992,983 |
| Neal Flomenberg | See Remarks | 76,940 |
| Sadiq Khan | Chief Commercial Officer | 1,169,618 |
| Jeffrey L. Feike | Director | 131,435 |
| Curtis L. Patton | Director | 139,192 |
| Susan M. Podlogar | Director | 123,678 |
| Keow Lin Goh | Director | 123,678 |
| Victor J. Sordillo | Director | 126,539 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Total | vs. prior year |
|---|---|---|---|---|
| Ryan Saadi, M.D., M.P.H. Chief Executive Officer | $501.00K | $9.92M | $10.42M | -88% |
| Kirti Desai Chief Financial Officer | $300.00K | $930.00K | $1.23M | +310% |
| Neal Flomenberg, M.D. Chief Scientific Officer and Global R&D Lead | $350.00K | $372.00K | $722.00K | +106% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Nov 5, 2021
- Offer price
- $10.00
- Securities offered
- 30,000,000
- Gross proceeds
- $300.00M
- Exchange
- Nasdaq
- First trading day
- Jan 3, 2022
- First-day close
- $10.05+0.5%
- Lock-up ends (est.)
- Jul 2, 2022
“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one-half of one redeemable warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings